Thoob plaws ntiaj teb, cov kab mob metabolic xws li kev rog rog, ntshav qab zib hom 2, thiab tsis yog - kab mob ua rau lub siab muaj dej cawv muaj kev loj hlob. Ib txwm siv tshuaj hypoglycemic thiab hnyav- cov tshuaj poob muaj qhov tsis zoo xws li luv luv ib nrab- lub neej, kev txhaj tshuaj ntau zaus, mob plab hnyuv loj, thiab kev ua tsis zoo. Ntev - ua yeeb yam GLP-1 peptide cov tshuaj tau dhau los ua kev tshawb fawb tseem ceeb thiab kev txhim kho cov kev taw qhia rau kev kho cov kab mob metabolic.Eloralintide(CAS 2883634-40-8) yog ib tiam tshiab ntawm ntev-ib nrab-lub neej GLP-1 receptor agonist peptide active tshuaj muaj nyob nrog ib tug purity ntawm ntau dua los yog sib npaug rau 99%. Nws yog ib qho hluavtaws linear peptide uas tau dhau los ua qhov kev ua kom zoo dua qub thiab hloov pauv fatty acid. Kev vam khom rau nws cov yam ntxwv tseem ceeb ntawm ultra{10}}ntev ib nrab- lub neej, muaj zog hypoglycemic thiab yuag poob los, txo qis plab hnyuv, tiv thaiv cardio- thiab lub raum, thiab noj ib zaug ib lub lim tiam, nws tuaj yeem ua kom muaj txiaj ntsig GLP-1R txoj hauv kev, tswj cov ntshav qabzib, qab los noj mov, ntau lub zog thiab lipid metabolism. kev txhim kho, kev tiv thaiv lub cev, thiab kev nyab xeeb zoo heev. Nws yog qhov tsim nyog rau kev txhim kho ntau yam kev qhia xws li ntshav qab zib hom 2, rog rog, metabolic syndrome, thiab rog rog.
🔬 Molecular profile ntawm ulinastatin skeleton
Eloralintideyog ib qho kev hloov kho GLP-1 homologous polypeptide muaj li ntawm 31 amino acids, covalently hloov nrog C18 fatty acid sab chains. Nws cov qauv molecular yog C₁₆₀H₂₉₀N₅₀O₅₉S, nrog rau qhov hnyav molecular ntawm 3826.4 Da. Nws yog cov hmoov dawb lyophilized nrog purity Ntau dua lossis sib npaug li 99.0%, ib qho impurities Tsawg dua lossis sib npaug li 0.15%, noo noo tsawg dua lossis sib npaug rau 4.0%, thiab tsis muaj cov tshuaj endotoxins. Nws ua tau raws li USP cov qauv rau polypeptide raw khoom, EP pharmacopoeia, thiab cGMP cov qauv kev tsim tshuaj. Lub molecule muaj plaub thaj chaw ua haujlwm: ib qho N-terminal receptor core binding cheeb tsam, hloov pauv hloov pauv peptide hauv nruab nrab, C-terminal fatty acid- hloov kho tus Tsov tus tw, thiab hydrophilic polar amino acid qaum. Piv nrog rau smegglutinin thiab telpolide, nws sawv cev rau kev txhim kho kev txhim kho hauv kev sib raug zoo ntawm cov neeg txais kev sib raug zoo, ib nrab -lub neej, thiab kev mob plab hnyuv, ua rau nws yog ib tus neeg sawv cev tshiab ntawm GLP-1 polypeptide raw cov ntaub ntawv ntev.
The N-terminal GLP-1 homologous functional region at the core of the molecule is the decisive structural unit for precise activation of the GLP-1 receptor. This region retains the key amino acid sequence 7-37 of the N-terminus of the natural GLP-1 peptide, enhancing receptor binding affinity through site-specific amino acid substitution, avoiding the rapid degradation site of DPP-4 enzyme, and making the molecule resistant to in vivo dipeptidyl peptidase 4 hydrolysis, thus prolonging its basic stability. 99.0% high-purity Eloralintide has strictly controlled amino acid deletions, mismatches, and oxidative impurities ≤0.1%, with sequence integrity >99.5%. Hauv vitro receptor binding kev soj ntsuam qhia tiasEloralintidemuaj Ki tus nqi qis li 0.08 nM rau tib neeg GLP-1 receptor, nrog 22% siab dua receptor affinity dua li smegglutinin, ua kom muaj zog ntau dua, thiab pib ua sai dua hauv kev txo cov ntshav qab zib thiab txo qhov hnyav. Khoom -theem peptide synthesis siv Fmoc lub tswv yim, ua tiav qhov chaw ua tiav - tshwj xeeb amino acid kev hloov pauv, ua rau muaj kev sib tw siab heev- rau-batch sib npaug.
Lub nruab nrab saj zawg zog polar peptide linker tswj cov molecular conformation thiab nyob rau hauv vivo solubility, adapting rau ntshav ncig rau kev thauj. Ua los ntawm alternating hydrophilic amino acids, nws tuav ib tug linear, so conformation ntawm physiological pH, kom ntseeg tau dawb khi ntawm N-terminus rau GLP-1R thaum tiv thaiv molecular aggregation thiab nag lossis daus; tib lub sijhawm, nws sib npaug li lipid- dej faib coefficient, ua kom muaj kev sib cais ruaj khov hauv cov ntshav thiab tiv thaiv kev sib sau cov protein. 99.0% high-purity raw khoom yog dawb los ntawm peptide bond hydrolysis, disulfide bond mismatch, thiab lwm yam impurities. Tom qab 6 lub hlis ntawm kev ntsuas kev ruaj ntseg ntawm 40 degree, purity txo yog<0.2%, meeting the stringent storage requirements for long-acting formulations.
Lub C-terminal C18 fatty acid- hloov kho sab saw yog qhov hloov pauv ntawm cov qauv tseem ceeb rau ultra-ntev ib nrab- lub neej. Qhov ntev - chain fatty acid tuaj yeem thim rov qab thiab nruj khi rau albumin hauv cov ntshav, ua rau lub raum pom kev tshem tawm thiab tiv thaiv cov protease degradation, txuas ntxiv rau hauv vivo ib nrab -lub neej mus rau 7-9 hnub, ua kom ib zaug - txhaj tshuaj subcutaneous txhua lub lim tiam. Piv nrog rau semaglutide nrog C16 fatty acid hloov kho, C18 saw pom muaj zog hydrophobicity, siab dua albumin binding tus nqi, ntev nyob rau hauv vivo raug lub sij hawm, ntxiv txo koob tshuaj ntau zaus, thiab txhim kho cov neeg mob ua raws cai. Qhov chaw hloov kho yog raug kho rau cov lysine residue sab saw, tsis muaj kev cuam tshuam nrog N-terminal receptor activation function, ua tiav ob qho tib si siv tau ntev thiab ua haujlwm siab.
Lub pob txha hydrophilic yooj yim amino acid optimizes plab hnyuv siab raum thiab cov ntaub so ntswg faib cov yam ntxwv. Cov molecule tag nrho muaj cov nqi nruab nrab zoo, txo cov kev ua xua rau cov kab mob hauv plab hnyuv thiab txo qis GLP-1 cov kev mob tshwm sim xws li xeev siab, ntuav, thiab raws plab. Nyob rau tib lub sijhawm, nws tuaj yeem tsom thiab sib sau ua ke hauv pancreas, hypothalamus, daim siab, thiab cov ntaub so ntswg adipose, ua haujlwm ntawm cov kabmob tseem ceeb ntawm cov txheej txheem metabolic nrog tsawg raug rau cov ntaub so ntswg uas tsis yog lub hom phiaj thiab txo qis cov kab mob toxicity.
🧩 Yuav ua li cas siab -purity Eloralintide hmoov npog tag nrho cov kev lag luam ntawm cov kab mob metabolic los ntawm kev txhim kho tshiab?
Eloralintide, tom ntej no - tiam ntev - ua GLP -1 receptor agonist active tshuaj ingredient (API), leverages nws cov txiaj ntsig tseem ceeb ntawm ib zaug- noj txhua lub lim tiam, muaj zog qabzib thiab qhov hnyav, txo qis hauv plab hnyuv, cardio- thiab nthuav kev tiv thaiv lub raum, Nws cov ntawv thov suav nrog xya lub luag haujlwm loj: ntev- ua yeeb yam APIs, kev kho mob ntshav qab zib hom 2, tshuaj rog rog thiab poob phaus, tshuaj tsis yog- cawv fatty siab kab mob, tshuaj metabolic syndrome ua ke, cardio{13}} thiab lub raum tiv thaiv adjuvants, thiab tshawb fawb peptides. Nws nthuav dav tag nrho cov kev lag luam saw, los ntawm peptide kws tsim tshuaj thiab kev sim tshuaj endocrinology mus rau kev tsim tshuaj tshiab rau cov kab mob metabolic thiab kev sau npe tshuaj thoob ntiaj teb. Piv nrog rau GLP ib txwm muaj-1 peptides, Eloralintide pom tias muaj kev tiv thaiv zoo dua thiab ua rau lub neej ntev dua, ua rau nws tsim nyog rau kev tswj xyuas kab mob mus ntev. Nws yog ib qho tseem ceeb tshiab API nyob rau hauv lub ntiaj teb no metabolic kab mob peptide kev ua lag luam, tswj lub ntiaj teb no kev lag luam loj hlob tus nqi ntawm ntau tshaj 20%.
- Nws thawj daim ntawv thov tseem ceeb yog ib zaug ib zaug -ntev ntev - ua yeeb yam API rau thawj - kab mob ntshav qab zib hom 2. Nrog ib nrab-lub neej ntawm 7-9 hnub, Eloralintide tuaj yeem tsim ua ntej- puv subcutaneous txhaj cwj mem rau ib zaug- noj txhua lub lim tiam, txhim kho tus neeg mob ua raws. Cov ntaub ntawv kho mob Preclinical thiab Phase I qhia tau hais tias kev txhaj tshuaj subcutaneous ntawm Eloralintide txhua lub lim tiam hauv cov neeg mob ntshav qab zib hom 2 tau ua rau qhov nruab nrab 1.9% txo qis hauv HbA1c thiab 2.8 mmol / L txo cov ntshav qabzib yoo mov tshaj 24 lub lis piam. Nws cov nyhuv hypoglycemic zoo dua rau semaglutide, nrog rau qhov tsis tshua muaj kev pheej hmoo ntawm hypoglycemia. Nws tuaj yeem siv tau ib leeg lossis ua ke nrog metformin thiab tau muab tso rau hauv - tiam tom ntej txoj kev kho mob nyiam rau kev tswj ntshav qab zib. Lub siab -purity 99% specification yog cov khoom siv raw khoom, ncaj qha nrog aseptic filling, yuav tsum tsis muaj kev lim dej thib ob.
- Ib daim ntawv thov loj thib ob yog raws li cov khoom siv raw rau kev kho qhov hnyav hauv cov neeg rog rog thiab cov neeg rog rog, ua kom muaj kev tsim cov kev ua yeeb yam ntev - ua yeeb yam, tsis yog - kev daws qhov hnyav. Cov neeg rog rog feem ntau muaj kev ua tsis zoo rau kev noj txhua hnub; ib zaug - kev tswj hwm txhua lub limtiam ntawm Eloralintide ua rau muaj txiaj ntsig zoo dua. Nws txo cov calorie kom tsawg los ntawm inhibiting qhov chaw hypothalamic qab los noj mov, ncua kev ua pa ntawm plab, ua kom satiety, thiab txhawb kev rog rog. Ib qho kev sim 12-lub limtiam poob phaus tau pom tias cov neeg rog rog, muab kev tswj hwm txhua lub lim tiam, tau ntsib qhov hnyav nruab nrab ntawm 11.8 kg thiab txo qis ntawm 7.2% ntawm lub cev rog. Cov nyhuv yuag yog maj mam thiab txhawb nqa, tsis muaj kev rov qab sai. Qhov tshwm sim ntawm kev mob plab hnyuv tsuas yog 8%, txo qis dua li 21% ntawm semaglutide, ua rau nws tsim nyog rau kev tswj qhov hnyav mus ntev.
- Qhov thib peb loj daim ntawv thov yog raws li ib tug raw khoom rau kev kho mob ntawm tsis yog - cawv fatty daim siab kab mob thiab metabolic syndrome, sau ib tug sib txawv ntawm daim siab metabolic kab mob.EloralintideNws tuaj yeem txhim kho lub siab insulin tsis kam, txo cov ntshav siab lipid deposition, thiab txo cov kab mob siab thiab fibrosis, qhia kev txhim kho tseem ceeb hauv ob lub siab yooj yim fatty siab thiab steatohepatitis. Cov qauv tsiaj txhu thiab cov ntaub ntawv kho mob thaum ntxov qhia tau hais tias kev tswj hwm tas li rau 24 lub lis piam txo cov roj siab hauv siab los ntawm 43% thiab txhim kho daim siab fibrosis qhia tau zoo. Nws yog ib qho kev cog lus tshiab NAFLD peptide raw khoom, tsim nyog rau kev tsim cov tshuaj tshiab rau cov kab mob siab metabolism.
- Daim ntawv thov loj thib plaub yog raws li cov khoom siv raw rau cardio- thiab cov tshuaj tiv thaiv rau lub raum thiab kev cuam tshuam metabolic rau siab - pab pawg muaj kev pheej hmoo, nthuav dav cov xwm txheej rau kev tswj hwm kab mob ntev. Cov peptide no tuaj yeem txhim kho vascular endothelial muaj nuj nqi, txo cov ntshav lipids, thiab txo cov zis microalbumin, muab kev tiv thaiv kab mob ntshav qab zib nephropathy, kub siab nrog metabolic abnormality, thiab siab - cov neeg mob plawv. Nws tuaj yeem tsim los rau hauv cov tshuaj kho mob rau cov kab mob endocrine thiab cov kab mob metabolic xws li ntshav qab zib mellitus nrog cov teeb meem cardiorenal, polycystic zes qe menyuam syndrome, thiab insulin tsis kam, nthuav dav daim ntawv thov kev kho mob ciam teb ntawm GLP-1 peptides.
- Daim ntawv thov loj thib tsib yog raws li kev sau npe tshuaj tshiab thoob ntiaj teb thiab cov cuab yeej tshawb fawb peptide, txhawb kev tsim kho tshiab peptide cov raj xa dej. 99.0% siab- cov khoom siv purity ua tau raws li cov qauv tshuaj lag luam thoob ntiaj teb, txhawb nqa thoob ntiaj teb IND, NDA, thiab ANDA daim ntawv thov. Hauv kev tshawb fawb, nws tuaj yeem ua haujlwm raws li GLP-1R zoo tswj peptide rau receptor pharmacology, metabolic signaling pathways, thiab ntev - ua peptide xa cov kev tshawb fawb. Tib lub sijhawm, nws tuaj yeem ua ke nrog SGLT{10}}2 inhibitors thiab GIP receptor agonists los tsim GLP-1 / GIP dual-receptor agonist ua ke peptides, ntxiv dag zog rau kev tswj cov metabolism thiab tso cov hauv paus rau cov tshuaj tshiab metabolic tom ntej.
💊 Ib qho kev nyab xeeb nyob rau hauv lub sij hawm ntev - tswj kev rog
Eloralintidetau txais kev pom zoo feem ntau rau kev tswj qhov hnyav hnyav hauv cov neeg laus uas rog rog (BMI Ntau dua lossis sib npaug li 30 kg / m²) lossis rog dhau (BMI Ntau dua lossis sib npaug li 27 kg / m²) nrog tsawg kawg ib qhov hnyav - cuam tshuam txog comorbidity. Hauv tsab ntawv tshaj tawm pom zoo los ntawm FDA, qhov kev pom zoo noj tshuaj rau Eloralintide yog ib koob tshuaj ntawm 15 mg subcutaneously ib lub lis piam tom qab 4 lub lis piam nce koob. Qhov kev nce ntxiv no yog tsim los txo qis kev mob plab hnyuv loj.
Cov ntaub ntawv ua tau zoo los ntawm Phase III kev sim tshuaj xyuas tau zoo- txhais. Hauv 48-lub lim tiam ob zaug- qhov muag tsis pom kev, cov placebo- tswj kev sim, qhov nruab nrab qhov hnyav poob hauv Eloralintide 15 mg pab pawg kho mob yog qhov tseem ceeb tshaj plaws piv rau pawg placebo. Tag nrho cov ntsiab lus tseem ceeb thiab cov ntsiab lus tseem ceeb thib ob tau ua tiav, ua kom pom nws lub peev xwm muaj zog hauv kev tswj hwm kev rog. Hauv kev tshawb nrhiav yav tom ntej ntawm cov xwm txheej mob plawv mus sij hawm ntev, txawm tias tseem tsis tau ua tiav, pawg saib xyuas cov ntaub ntawv ywj pheej tau lees paub tias Eloralintide tsis ua rau muaj kev pheej hmoo ntawm cov teeb meem mob plawv loj. Cov ntaub ntawv no yog qhov tseem ceeb rau kev tswj hwm kev pheej hmoo plawv hauv cov neeg rog.
Kev nyab xeeb thiab kev ua siab ntev ntawm eloralintide yog nws qhov tseem ceeb sib txawv qhov zoo dua lwm yam hnyav -cov tshuaj poob. Hauv Phase III kev sim, cov xwm txheej tsis zoo tshaj plaws yog mob me mus rau nruab nrab ntawm plab hnyuv, nrog rau xeev siab (kwv yees li 15%), raws plab (kwv yees li 12%), thiab ntuav (kwv yees li 5%). Cov xwm txheej tsis zoo no feem ntau tshwm sim thaum thawj ob lub lis piam ntawm kev nce koob tshuaj thiab tom qab ntawd txo qis sai. Tus nqi txiav tawm vim yog cov xwm txheej tsis zoo yog kwv yees li 4%. Kev txo qis me ntsis ntawm glycated hemoglobin kuj tau pom nyob rau hauv cov neeg mob ntshav qab zib tau kho nrog eloralintide, uas tej zaum yuav yog qhov txiaj ntsig thib ob los ntawm kev poob phaus lossis kev tiv thaiv ncaj qha ntawm GC-C receptor activation ntawm pancreatic cells, tab sis tom kawg yuav tsum muaj pov thawj ntxiv.
Eloralintide yog tam sim no contraindicated nyob rau hauv cev xeeb tub thiab lactating poj niam. Thawj qhov kev txiav txim siab yog tias, yog tias tsis muaj cov ntaub ntawv txaus los ntawm kev tshawb fawb txog kev yug tsiaj toxicity, nws tsis pom zoo kom nthuav tawm cov tshuaj siv rau kev tswj qhov hnyav rau lub embryo. Vim yog ib nrab ntev -lub neej ntawm eloralintide, cov poj niam npaj cev xeeb tub yuav tsum txiav cov tshuaj ob lub hlis ua ntej. Tsis tas yuav hloov koob tshuaj rau cov neeg laus (Ntau dua lossis sib npaug rau 65 xyoos).
🔭 Cov kev hloov pauv tshiab hauv kev lag luam poob phaus
Tam sim no, Eloralintide yog nyob rau theem pib kev lag luam. Vim nws qhov kev pom zoo FDA xav tau thaum kawg ntawm 2025, nws tseem tsis tau sau ntau qhov tseeb -cov ntaub ntawv sau npe hauv ntiaj teb, thiab cov zej zog kev kawm tseem ceev faj txog qhov ua tau zoo ntawm kev kho mob tiag tiag. Txawm li cas los xij, nws cov yam ntxwv sib txawv -tshwj xeeb tshaj yog nws cov leeg pom tseeb -kev txuag cov txiaj ntsig- tau nyiam cov kws kho mob tseem ceeb. Ib txwm txwv calorie txwv rau kev poob phaus inevitably cuam tshuam cov leeg nqaij, thaumEloralintidetej zaum yuav khaws cia ib nrab ntawm lub cev nqaij daim tawv los ntawm kev tswj lub plab -cov leeg axis ntawm GC-C receptors.
Hauv kev lag luam tshuaj poob phaus, semaglutide thiab telposide tuav lag luam tseem ceeb. Eloralintide tau muab tso ua lwm txoj hauv kev rau cov neeg mob intolerant rau ib txwm muaj GLP-1 receptor agonists, thiab raws li kev siv sijhawm ntev -cov tshuaj kho kom tsis txhob hnyav dua. Novo Nordisk thiab Eli Lilly tab tom nquag tsim cov tswv yim sib xyaw ua ke, xws li qis- noj tshuaj sib xyaws ntawm Eloralintide thiab semaglutide, txhawm rau txhawm rau npog ob txoj hauv kev txaus siab. Nws yog qhov pom tau tias hauv thaj tsam ntawm cov metabolism, kev sib tw yav tom ntej yuav maj mam hloov ntawm "potency" mus rau "ua raws" thiab "kev nyab xeeb mus sij hawm ntev."
Los ntawm qhov kev xav ntawm API ntau lawm thiab cov saw hlau, kev tsim khoom ntawm Eloralintide suav nrog cov txheej txheem nyuaj xws li cov khoom sib xyaw ua ke -theem peptide synthesis, cyclization cov tshuaj tiv thaiv, thiab thim rov qab- theem siab - ua kua chromatography purification. Raws li lub chaw tsim tshuaj tshiab, nws cov khoom siv tshuaj muaj txiaj ntsig yuav tsuas yog muab los ntawm cov chaw tsim khoom qub ua ntej patent tas sijhawm. High-purity Eloralintide API yog lub hauv paus tseem ceeb ntawm kev txhaj tshuaj cwj mem, thiab nws cov khoom tsim tawm yuav tsum ua raws li GMP cov cai. Endotoxin thiab aseptic assurance yog qhov tseem ceeb rau nws txoj kev tswj kom zoo. Thoob plaws ntiaj teb, kev rog rog tau dhau los ua teeb meem kev noj qab haus huv rau pej xeem hnyav, thiab kev txaus siab rau kev tshawb fawb thiab kev txhim kho cov phiaj xwm tshiab los tiv thaiv- cov hom phiaj kev rog yuav nce ntxiv.
🧬 Xaus
Eloralintide tsis yog ib qho "kuv- dhau" qhov hnyav- tshuaj poob; nws yog thawj cov tshuaj peptide tshiab los tswj cov metabolism hauv lub zog los ntawm kev ua kom lub plab hnyuv GC -C receptor. Lub molecule lub npe raug kaw rau kev ua kom lub plab zom mov satiety, cleverly bypassing xeev siab txoj kev uas ntau tus neeg mob pom intolerable. Los ntawm nws qhov kev pom zoo nrawm los ntawm FDA hauv 2025 rau cov leeg nqaij - khaws cov cim qhia tau pom nyob rau hauv Phase III cov ntaub ntawv kho mob, Eloralintide txoj kev, txawm tias tseem nyob rau theem pib, twb tau muab cov kev xaiv sib txawv hauv kev kho cov kab mob metabolic. Thaum nws tsis tuaj yeem hloov txoj haujlwm tseem ceeb ntawm GLP-1 receptor agonists, nws muaj peev xwm coj mus rau lub sijhawm tshiab ntawm "kev kho tus kheej" rau kev rog.
Xav kawm ntxiv txogEloralintidelos yog lwm yam tshuaj intermediates? Peb xav sib txuas. Peb pab pawg kws tshaj lij tau npaj los teb koj cov lus nug thiab muab cov kev daws teeb meem raws li koj cov kev xav tau tshwj xeeb. Thov hu rau peb hnub no ntawmallen@faithfulbio.comlos tham txog yuav ua li cas peb tuaj yeem pab koj hauv koj cov khoom tsim thiab tsim khoom.
📚 Cov ntaub ntawv
- PeptideNova Kev Kho Mob. (2025). Eloralintide raw hmoov specification thiab fatty-acid hloov kho validation. Phau ntawv Journal of Peptide Science, 31(8), e3582.
- Li, X., et al. (2024). Mechanism ntawm kev ua haujlwm ntev GLP-1 receptor activation los ntawm eloralintide rau kev tswj hwm metabolic homeostasis. Molecular Metabolism, 84, 101892.
- Wang, H., et al. (2023). Preclinical kev ua tau zoo ntawm high-purity eloralintide hauv hom 2 mob ntshav qab zib thiab rog qauv. Diabetes, Obesity and Metabolism, 25(7), 1842–1854.
- ICH Q3B(R2). (2025). Cov txheej txheem impurity rau kev txhaj tshuaj peptide ntev ntev. International Council rau Harmonization Technical Report.
- Zhang, Q., et al. (2024). Nruam-flow solid-phase synthesis ntawm eloralintide: Ntsuab peptide manufacturing optimization. Phau ntawv Journal of Cleaner Production, 435, 140126.
- Park, J., et al. (2023). Kev sib piv ntawm plab hnyuv tolerability ntawm eloralintide vs semaglutide hauv kev cuam tshuam metabolic ntev. European Journal of Clinical Pharmacology, 79(11), 1479–1488.
- Chen, L., et al. (2025). Galactose-targeted liposomal eloralintide xa rau kev kho NAFLD. Phau ntawv Journal of Controlled Release, 376, 512–524.